

HyQvia (Immune Globulin Infusion 10%(Human) with Recombinant Human Hyaluronidase)

Provider Order Form rev 11/11/2024

PATIENT INFORMATION	Referral Status	: □ New Referra	ıl □ Updated Oı	rder 🗆 Ord	der Renewal	
Patient Name:		DOB:	Patient Ph	none:		
Patient Address:			Patient Email:			
Allergies:		□ NKDA Wei	ght (lbs/kg):	Height (ir	n/cm):	
Sex: □ M / □ F Date of Last Infusion:	Next Due Dat	e: P	referred Location:			
DIAGNOSIS (Please provide ICD-10 code in sp	aco providod)					
Primary Immunodeficiency:	uce provided)	Chronic Inflamr	natory Demyelinati	ng Polvneuror	pathy:	
Other:				0 - 7 1	,	
THERAPY ADMINISTRATION (Select one)		LABORATORY OR				
Chronic Inflammatory Demyelinating Polyneuropathy • Doses less than or equal to 0.4 g/kg can be administered without ramp-up • Patients must be on stable doses of IVIG for 12 weeks before switching to HYQVIA □ Patients transitioning from IVIG tx, administer HyQvia at the same		☐ CBC w/ diff ☐ CMP	☐ at each dose☐ at each dose	□ eve	ry: ry:	
					· y ·	
		PRE-MEDICATION ORDERS				
dose and frequency as the previous IV tx , after the init	ial dose ramp-up	☐ Tylenol ☐ 500mg / ☐ 650mg PO ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP				
as indicated per the manufacturer.						
DoseGM subcutaneously Frequency: □every 2 weeks/ □every 3 weeks□/ever	v 4 weeks	☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP				
Trequency. Devery 2 weeks, Devery 5 weeks by ever	y i weeks	☐ Solumedrol ☐ 40mg / ☐ 125mg IVP				
Primary Immunodeficiency		☐ Other:				
☐ Patients transitioning from IVIG tx, administer HyQ		NURSING				
dose and frequency as the previous IV tx, after the ini	tial dose ramp-	✓ Provide nursing care per Nursing Procedure, including Hypersensitivity				
up as indicated per the manufacturer. Dose:GM subcutaneously Frequency: □every 3 weeks□/every 4 weeks		Reaction Management Protocol and post-procedure observation				
☐ New to SCIG treatment or transitioning from SCIG, administer HyQvia at 300mg/kg to 600mg/kg at 3- or 4-week intervals, after the initial ramp up as indicated by the manufacturer. Dose:GM subcutaneously		CIDP ramp up PI ramp up if switching Ramp up if switching from SC from IVIG or new to SCIG				
		Wk 1 -no tx	Wk 1 total gmX0.25	3 weeks	4 weeks	
		Wk 2&3 total gm x0.25	5 Wk 2 total gmX0 5	Wk 1 total	Wk 1 total	
Frequency: \square every 3 weeks/ \square every 4 weeks.		TWK ZGG total gill xo.z.	VIK Z total gillino.5	gmX0.33 Wk 2 total	gmx0.25 Wk 2 total	
ADDITIONAL ORDERS		Wk 4 total gm X0.50	Wk 4 total gmX0.75	gmx0.67	gmx0.5	
		Wk 6 total gm x0.75	Wk 7 total dose	Wk 4 total dos	Wk 4 total	
		Wk 9 total dose			gmX0.75 Wk 7 total dose	
			1	-	"	
PROVIDER INFORMATION						
Preferred Contact Name:	Preferred Contact Email:					
Ordering Provider:		Provider NPI:				
Referring Practice Name:	Ph	Phone: Fax:				
Practice Address:	City:		State: Zip Code:			
REQUIRED DOCUMENTATION CHECKLIS	T (Additional docum	entation required	for processing an	d insurance d	approval)	
Required Documentation: Patient demos, copy	of front and back of p	orimary and secon	dary insurance, 2 r	most recent C	OVN including	
treatment failures or contraindications. EMG (dx $$	CIDP)					
Required Labs: Immunoglobulin levels, Renal fur	nction, CRP/ESR, ANA	۸,				
Provider Name (print)	Provider Signature			Date		